Results 191 to 200 of about 5,862,672 (337)
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
A step further in our commitment to support early career researchers (ECRs). [PDF]
FEBS Open BioFuentes S, De la Rosa MA.
europepmc +1 more source
Molecular Oncology, EarlyView.Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Icon of the last issue - Prof. C. Balakrishnan
Indian Journal of Plastic Surgery, 2009 Saleem Lakshmi
doaj
New Advances in Palliative Care-State of the Field, Its Challenges and Advances at the End of the Year 2025. [PDF]
Healthcare (Basel)Bollig G, Zelko E.
europepmc +1 more source
A Bibliometric Analysis of Tax Evasion Issues in the Last Decade
, 2021 Bani Alkausar +2 more
openalex +2 more sources
Molecular Oncology, EarlyView.HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto +13 more
wiley +1 more source